The international academic journal Cell Research published the latest research results on the synthesis of rare ginsenoside compound K (CK) from monosaccharides by yeast Online Production of bioactive ginsenoside compound K in metabolically engineered yeast。 This study found and identified a UDP glycosyltransferase (ugtpg1) from ginseng, which specifically catalyzes the c-20s hydroxyl glycosylation of damma type tetracyclic triterpenoids. It was co expressed with the artificially constructed protopanaxadiol synthesis pathway in yeast chassis cells, realizing the biosynthesis from monosaccharide to rare ginsenoside compound K.
Ginseng, known as the "king of herbs", has been used in China, South Korea and Japan for health, disease prevention and anti-aging for thousands of years. Ginsenosides are the main effective components of ginseng, which belong to triterpenoids. At least 60 ginsenosides have been isolated from ginseng. rareginsenoside compound KIt is the main active ingredient detected in the blood after oral administration of ginseng or total ginsenosides, and is considered to be the main active molecule that ginseng is absorbed into the blood and plays a role after metabolism in the body.GinsenosidesCK has been reported to have a variety of potential medicinal values such as anticancer, liver protection, anti-inflammatory and diabetes treatment. Due to its effect in the prevention and treatment of arthritis, preclinical experiments have been completed. In 2013, the State Food and Drug Administration approved the implementation of relevant clinical experiments.
Since CK has not been detected in total ginsenosides, it is mainly obtained by glycosylation of protopanaxadiol saponins at present. Such preparation methods depend on the supply of ginsenoside resources. As the wild ginseng resources have been basically exhausted, and the artificial cultivation of ginseng is faced with problems such as long growth cycle, pests and diseases, and continuous cropping obstacles, the supply, quality and safety of ginsenoside resources are facing challenges.
The use of synthetic biology to synthesize ginsenosides has attracted great attention in recent years. In 2011, Korean scientists constructed yeast cells that can produce protopanaxadiol based on cloning and identification of key enzymes in the protopanaxadiol synthesis pathway. In 2012, they identified cytochrome P450 (cyp716a53v2) that catalyzes protopanaxadiol to produce protopanaxatriol. At the end of January this year, the research group of zhangxueli, a researcher at Tianjin Institute of industrial biotechnology, Chinese Academy of Sciences, and the research group of huangluqi, a researcher at the traditional Chinese medicine resource center, Chinese Academy of traditional Chinese medicine, cooperated to build a "ginseng yeast" cell factory that simultaneously produces oleanolic acid, protopanaxadiol and protopanaxatriol. The above work provides the technology of synthesizing ginsenosides by yeast, which lays the foundation for realizing the synthesis of ginsenosides in a real sense.
In this study, a yeast cell factory capable of producing 'unnatural ginsenosides' was constructed for the first time, realizing the biosynthesis of ginsenosides. Based on the discovery and identification of a new compound (20s-o- β - (d-glucosyl) -dammarenediol II) in recombinant yeast cells, it was confirmed that there were two syntheticGinsenosidesThe metabolic pathway of CK, which implies that there are similar two parallel ginsenoside synthesis pathways in ginseng. This research is an important part of the "973" project "construction and integration of new functional artificial biological devices". The organizer of the project is zhaoguoping, academician of Institute of plant physiology and ecology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences. The research work was completed by the zhouzhihua research group of the Key Laboratory of synthetic biology of the Chinese Academy of Sciences and the yuejianmin research group of the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences. At the same time, it also received funding from the important direction of the knowledge innovation project of the Chinese Academy of Sciences.
March 13, 2014 source: Shanghai Life Sciences
Biosynthesis of rare ginsenoside compound K
Release Date：2019/4/23 14:07:25